Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nexys Therapeutics URAT1 compound 22k
- Development stage
- Unknown
- Lead developer
- Nexys Therapeutics
01
Overview
Nexys Therapeutics URAT1 compound 22k: sourced facts only. name: "To address these limitations, we designed and optimized a novel series of 6-azaindole URAT1 inhibitors, culminating in the lead candidate 22k." [PMID:40529089]; target: "To address these limitations, we designed and optimized a novel series of 6-azaindole URAT1 inhibitors, culminating in the lead candidate 22k." [PMID:40529089]; developer: "Nexys Therapeutics Inc., 9276 Scranton Rd, Ste 500, San Diego, California 92121, United States." [PMID:40529089]
02
Targets
URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on Nexys Therapeutics URAT1 compound 22k.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nexys Therapeutics URAT1 compound 22k.